EUVIMEDEUVIMED entdecken
Crossref

Cladribine‐ and decitabine‐containing conditioning regimen has a low post‐transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome

Xiwen Tong, Mengyuan Li, Jie Jin, Yi Li, Li Li, Yizhou Peng, Lifang Huang, Bin Xu, Fankai Meng, Xia Mao iD, Liang Huang, Wei Huang und 1 weitere

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34419 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Xiwen Tong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Graft vs Host Disease, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To reduce the risk of relapse after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), there have been continuing efforts to optimize the conditioning regimens. Our study aimed to analyze the risk factors associated with the relapse of relapsed/refractory (R/R), high‐risk acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (MDS) post‐transplant and the efficacy of a new conditioning regimen involving decitabine and cladribine. Clinical data of 125 patients with R/R AML, high‐risk AML and high‐risk MDS who underwent allo‐HSCT were collected. In addition, 35 patients with R/R AML, high‐risk AML and high‐risk MDS received treatment with a new conditioning regimen including decitabine and cladribine. Cox regression analysis was used to identify risk factors associated with OS, RFS and relapse. Among 125 patients who underwent allo‐HSCT, CR before allo‐HSCT and matched sibling donors were independent protective factors for OS. DNMT3A abnormality was an independent risk factor for both relapse and RFS. Among 35 patients who received a new conditioning regimen containing decitabine and cladribine, only six patients relapsed and 1‐year cumulative incidence of relapse was 11.7%. Moreover, this new regimen showed efficient MRD clearance early after allo‐HSCT. The combined decitabine‐ and cladribine‐based conditioning regimen showed a low relapse rate and a high survival without an increased incidence of GVHD or adverse effects and thus has potential for use in allo‐HSCT for R/R AML, high‐risk AML and high‐risk MDS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseLeukemia, Myeloid, AcuteMyelodysplastic SyndromesHematopoietic Stem Cell TransplantationHumansCladribineDecitabineChronic DiseaseRecurrenceRetrospective Studies

Stichwörter der Autor:innen

acute myeloid leukemiaallogeneic hematopoietic stem cell transplantationcladribinedecitabinemyelodysplastic syndrome

Substanzen

CladribineDecitabine

Autor:innen und Institutionen

  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

ORCID-Profile: Xia Mao, Donghua Zhang

Zitieren

APA

Tong, X., Li, M., Jin, J., Li, Y., Li, L., Peng, Y., Huang, L., Xu, B., Meng, F., Mao, X., Huang, L., Huang, W., & Zhang, D. (2023). Cladribine‐ and decitabine‐containing conditioning regimen has a low post‐transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome. International Journal of Cancer. https://doi.org/10.1002/ijc.34419

Vancouver

Tong X, Li M, Jin J, Li Y, Li L, Peng Y, et al. Cladribine‐ and decitabine‐containing conditioning regimen has a low post‐transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome. International Journal of Cancer. 2023. doi:10.1002/ijc.34419

BibTeX
@article{Tong2023,
  author = {Tong, Xiwen and Li, Mengyuan and Jin, Jie and Li, Yi and Li, Li and Peng, Yizhou and Huang, Lifang and Xu, Bin and Meng, Fankai and Mao, Xia and Huang, Liang and Huang, Wei and Zhang, Donghua},
  title = {Cladribine‐ and decitabine‐containing conditioning regimen has a low post‐transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34419}
}
Kostenlos starten →